2020
Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia.
Low J, Sooi K, Huang Y, Chan G, Ang Y, Chong W, Tan H, Ngoi N, Choo J, Lee M, Muthu V, Asokumaran Y, Walsh R, Wong R, Chan Z, Soo R, Sundar R, Yong W. Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia. Journal Of Clinical Oncology 2020, 38: e19385-e19385. DOI: 10.1200/jco.2020.38.15_suppl.e19385.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerProgression free survivalFree survivalFixed doseTreatment of non-small cell lung cancer patientsOncogenic driversNon-small cell lung cancer patientsTreatment of non-small cell lung cancerCell lung cancer patientsResponse rateTreated with pembrolizumabDose of pembrolizumabEfficacy of pembrolizumabKaplan Meier methodUS Food and Drug AdministrationSurvival of patientsCell lung cancerLow dose groupLung cancer patientsNational University HospitalFood and Drug AdministrationStandard of careECOG 0Overall survival
2014
Immunotherapy in the treatment of non-small cell lung cancer
Sundar R, Soong R, Cho B, Brahmer J, Soo R. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014, 85: 101-109. PMID: 24880938, PMCID: PMC4332778, DOI: 10.1016/j.lungcan.2014.05.005.Peer-Reviewed Educational MaterialsConceptsImmune response to tumorsTreatment of non-small cell lung cancerNon-small cell lung cancerProlonged clinical responsesImmune checkpoint modulatorsImmune checkpoint pathwaysPD-L1 inhibitorsResponse to tumorsCell lung cancerCTLA-4PD-1PD-L1Tolerable toxicityTumor immunosurveillanceCheckpoint modulatorsCo-stimulatoryCo-inhibitoryClinical responseImmunotherapeutic agentsPredictive biomarkersImmune destructionLung cancerTreatment selectionImmune systemInhibitory molecules